The 2004 immunization schedule: Small change and shorter shelf life

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

The news is full of stories about monkeypox, the recent changes to COVID-19 guidance, and the return of polio cases. What do clinicians need to know?

The Centers for Disease Control and Prevention is advising providers to prioritize 100 mg doses of nirsevimab, a monoclonal antibody FDA-approved to prevent respiratory syncytial virus (RSV), for infants at the highest risk of severe RSV disease.

Contemporary Pediatrics sat down with Tina Q. Tan, MD, FAAP, FIDSA, FPIDS, to discuss what's known about the variant. She also discusses the latest on the vaccine for children aged younger than 5 years.

Eculizumab and anakinra should be considered in critically ill patients with severe infections that require immunomodulating therapies for life-threatening dysregulation, according to a poster session at the 2023 American Academy of Pediatrics National Conference & Exhibition.

A sneak peek at some of the most exciting sessions at this year's American Academy of Pediatrics national conference.